Abbott Laboratories Asks Regulators to Approve New Dose of AIDS Drug Kaletra for Children
July 23, 2007
Abbott Laboratories on Friday said it is seeking approval from the U.S. Food and Drug Administration and European regulators for lower-dose versions of its AIDS drug Kaletra, which is also marketed as Aluvia. The new version is expected to be suitable for pediatric use and would cost half as much as the full-strength formulation.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.